Two combination therapies shrink melanoma brain metastases in more than half of patients

Binimetinib Improves PFS in NRAS-mutant Melanoma

Vemurafenib

Dabrafenib

Ipilimumab

Peginterferon alfa-2b

Trametinib

Nivolumab

Pembrolizumab

Talimogene laherparepvec

Cobimetinib

Penile cancer